image credit- freepik
AstraZeneca has announced plans to establish a commercial cell therapy manufacturing and supply base and innovation centre in Shanghai, becoming the first global leading biopharmaceutical company with end-to-end cell therapy capabilities in China. On the same day, the company signed a Memorandum of Understanding on multi-party cooperation with the Shanghai Municipal Science and Technology Commission and leading scientific research and financial institutions in the UK.
AstraZeneca will build a dedicated cell therapy commercial production and supply base in the Lingang New Area of the Shanghai Free Trade Zone for the commercial production and supply of autologous CAR-T cell therapies in China and other Asian markets.
Among them is AZD0120, a BCMA/CD19 dual-target CAR-T cell therapy developed based on Genxi Biotech's FasTCAR rapid manufacturing platform, which is currently undergoing clinical research in the field of multiple myeloma and autoimmune diseases.
The company will also establish the AstraZeneca Genxi Cell Therapy Innovation Center in Shanghai Zhangjiang Hi-Tech Park, covering early research, viral vector and plasmid development, analytical testing, clinical production and registration support.
AstraZeneca, together with the Shanghai Municipal Science and Technology Commission, the University of Glasgow, King's College London and HSBC, has announced the joint launch of the "Shanghai-UK Life Sciences Innovation Ecological Cooperation Programme".
